New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
09:02 EDTSNY, INWKSanofi, InnerWorkings sign global marketing partnership
InnerWorkings (INWK) has been selected as a global marketing partner of Sanofi (SNY). Under this agreement, InnerWorkings will oversee the creation, production, and management of Sanofiís worldwide promotional items, with a special focus on implementing high standards for corporate and social responsibility across global operations. Additionally, InnerWorkings will drive enhanced innovation, stewardship, and consistency across Sanofiís global efforts. InnerWorkings and Sanofi began its partnership in 2013 with a pilot program to support Sanofiís work in 15 countries across the Americas, Europe and Africa. Throughout the rest of 2014, InnerWorkings will expand this solution to dozens more countries and regions.
News For SNY;INWK From The Last 14 Days
Check below for free stories on SNY;INWK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
16:48 EDTINWKInnerWorkings files to sell 4.84M shares of common stock for holders
Subscribe for More Information
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
September 5, 2014
07:47 EDTINWKInnerWorkings management to meet with Barrington
Subscribe for More Information
September 3, 2014
12:49 EDTSNYSanofi reports Dengue vaccine candidate achieves its phase 3 primary endpoint
Sanofi Pasteur, the vaccines division of Sanofi, announced that the final landmark phase 3 efficacy study of its dengue vaccine candidate in Latin America successfully achieved its primary clinical endpoint. Results showed an overall significant reduction of 60.8% of dengue disease cases in children and adolescents 9-16 years old after a three-dose vaccination schedule. Importantly, efficacy was observed against each of the four dengue serotypes. Additional observations of the results showed a clinically important reduction by 80.3% in the risk of hospitalization due to dengue during the study. The results also showed in the study population an efficacy against dengue haemorrhagic fever, the severe form of dengue, which is consistent with the results released from Sanofiís phase 3 dengue study in Asia. Lastly, the results suggest better protection in case of prior exposure to dengue.
September 2, 2014
20:26 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
13:58 EDTSNYRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
08:35 EDTSNYIntrexon enters into ECC with Sanofi subsidiary to develop APIs
Subscribe for More Information
07:21 EDTSNYRegeneron data positive, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use